EU plans to shorten the regulatory data protection for new medicines will reduce investment in R&D and stifle innovation, Stefan Woxström, senior vice president of AstraZeneca Europe and Canada, has warned. “Of course, that will play a role when companies are looking into where they will put their future investments in new types of medicines,” he told Science|Business.
AstraZeneca to focus on rare diseases, continuing local investments thesundaily.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thesundaily.my Daily Mail and Mail on Sunday newspapers.
They will boost cooperation in disease prevention and control, pharmaceutical research, development and manufacturing, and sustainable health system development